| Overview |
| bs-1815R-Cy7 |
| KCNH2 Polyclonal Antibody, Cy7 Conjugated |
| FCM |
| Human, Rat |
| Mouse, Dog, Pig, Horse, Rabbit |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human HERG |
| 1001-1159/1159 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 3757 |
| Q12809 |
| Cell membrane |
| ERG1; HERG; LQT2; SQT1; ERG-1; H-ERG; HERG1; Kv11.1; Potassium voltage-gated channel subfamily H member 2; Eag homolog; Ether-a-go-go-related gene potassium channel 1; Eag-related protein 1; Ether-a-go-go-related protein 1; hERG-1; Voltage-gated potassium channel subunit Kv11.1; KCNH2; ERG |
| Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation. |
| Application Dilution |
| FCM |
1:20-100 |
Powered by Bioz